101 related articles for article (PubMed ID: 10088172)
41. Renal clearance of technetium-99m-MAG3: normal values.
Russell CD; Li Y; Nadiye Kahraman H; Dubovsky EV
J Nucl Med; 1995 Apr; 36(4):706-8. PubMed ID: 7699471
[No Abstract] [Full Text] [Related]
42. 99Tcm-MAG3: problems with radiochemical purity testing.
Murray T; McKellar K; Owens J; Watson WS; Hilditch TE; Elliott AT
Nucl Med Commun; 2000 Jan; 21(1):71-5. PubMed ID: 10717905
[TBL] [Abstract][Full Text] [Related]
43. Elimination of the influence of total renal function on renal output efficiency and normalized residual activity.
Nimmon CC; Sámal M; Britton KE
J Nucl Med; 2004 Apr; 45(4):587-93. PubMed ID: 15073254
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetic alteration of (99m)Tc-MAG3 using serum protein binding displacement method.
Nishi K; Kobayashi M; Nishii R; Shikano N; Takamura N; Kuga N; Yamasaki K; Nagamachi S; Tamura S; Otagiri M; Kawai K
Nucl Med Biol; 2013 Apr; 40(3):366-70. PubMed ID: 23312701
[TBL] [Abstract][Full Text] [Related]
45. Comparative evaluation of 99Tcm-Hynic-HSA and 99Tcm-MAG3-HSA as possible blood pool agents.
Verbeke K; Hjelstuen O; Debrock E; Cleynhens B; De Roo M; Verbruggen A
Nucl Med Commun; 1995 Nov; 16(11):942-57. PubMed ID: 8587761
[TBL] [Abstract][Full Text] [Related]
46. Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.
Engfeldt T; Orlova A; Tran T; Bruskin A; Widström C; Karlström AE; Tolmachev V
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):722-733. PubMed ID: 17146656
[TBL] [Abstract][Full Text] [Related]
47. Noninvasive imaging of human telomerase reverse transcriptase (hTERT) messenger RNA with 99mTc-radiolabeled antisense probes in malignant tumors.
Liu M; Wang RF; Zhang CL; Yan P; Yu MM; Di LJ; Liu HJ; Guo FQ
J Nucl Med; 2007 Dec; 48(12):2028-36. PubMed ID: 18006621
[TBL] [Abstract][Full Text] [Related]
48. [Nuclear nephrology].
Inoue T
Kaku Igaku; 1997 Dec; 34(12):1149-53. PubMed ID: 9494337
[TBL] [Abstract][Full Text] [Related]
49. Prediction of renal transplant survival from early postoperative radioisotope studies.
Russell CD; Yang H; Gaston RS; Hudson SL; Diethelm AG; Dubovsky EV
J Nucl Med; 2000 Aug; 41(8):1332-6. PubMed ID: 10945523
[TBL] [Abstract][Full Text] [Related]
50. Reproducibility of technetium-99m mercaptoacetyltriglycine clearance.
Piepsz A; Tondeur M; Kinthaert J; Ham HR
Eur J Nucl Med; 1996 Feb; 23(2):195-8. PubMed ID: 8925855
[TBL] [Abstract][Full Text] [Related]
51. A comparison of the renal handling of 99Tcm-DTPA and 99Tcm-MAG3 in hypertensive patients using an uptake technique.
Rutland MD; Que L
Nucl Med Commun; 1999 Sep; 20(9):823-8. PubMed ID: 10533187
[TBL] [Abstract][Full Text] [Related]
52. 99mTc-MAEC complexes: new renal radiopharmaceuticals combining characteristics of (99m)Tc-MAG3 and (99m)Tc-EC.
Taylor AT; Lipowska M; Hansen L; Malveaux E; Marzilli LG
J Nucl Med; 2004 May; 45(5):885-91. PubMed ID: 15136640
[TBL] [Abstract][Full Text] [Related]
53. Uptake kinetics of 99mTc-MAG3-antisense oligonucleotide to PCNA and effect on gene expression in vascular smooth muscle cells.
Zhang YR; Zhang YX; Cao W; Lan XL
J Nucl Med; 2005 Jun; 46(6):1052-8. PubMed ID: 15937319
[TBL] [Abstract][Full Text] [Related]
54. Reproducibility of technetium-99m-MAG3 clearance using the Bubeck method.
Werner E; Blasl C; Reiners C
J Nucl Med; 1998 Jun; 39(6):1066-9. PubMed ID: 9627345
[TBL] [Abstract][Full Text] [Related]
55. Effects of alternative reconstitution procedures on the labelling efficiency and in vitro stability of 99Tcm-labelled radiopharmaceuticals.
Bogsrud TV; Chen MN; Herold TJ; Mahoney DW; Hung JC
Nucl Med Commun; 1999 Jan; 20(1):61-5. PubMed ID: 9949414
[TBL] [Abstract][Full Text] [Related]
56. Captopril-induced changes in MAG3 clearance in patients with renal arterial stenosis and the effect of renal angioplasty.
Müller-Suur R; Tidgren B; Fehrm A; Lundberg HJ
J Nucl Med; 2000 Jul; 41(7):1203-8. PubMed ID: 10914910
[TBL] [Abstract][Full Text] [Related]
57. Secretion of radioactivity in breast milk following administration of 99Tcm-MAG3.
Evans JL; Mountford PJ; Herring AN; Richardson MA
Nucl Med Commun; 1993 Feb; 14(2):108-11. PubMed ID: 8429987
[TBL] [Abstract][Full Text] [Related]
58. Comparison of 99Tcm-mercaptoacetyltriglycine and 131I-orthoiodohippurate in determination of effective renal plasma flow (ERPF).
Abdel-Dayem HM; Sadek S; al-Bahar R; Sabha M; el-Sayed M
Nucl Med Commun; 1989 Feb; 10(2):99-107. PubMed ID: 2525236
[TBL] [Abstract][Full Text] [Related]
59. Reproducibility of quantitative 99Tcm-MAG 3 measurements in rats.
Tondeur M; Piepsz A; Jeghers O; Froideville JL; Ham HR
Nucl Med Commun; 1989 Jun; 10(6):431-4. PubMed ID: 2528088
[TBL] [Abstract][Full Text] [Related]
60. Comparative study of renal scintigraphy with 99Tcm-mercaptoacetyltriglycine and 123I-orthoiodohippurate.
Itoh K; Tsukamoto E; Kakizaki H; Nonomura K; Furudate M
Nucl Med Commun; 1993 Aug; 14(8):644-52. PubMed ID: 8371889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
